Matches in SemOpenAlex for { <https://semopenalex.org/work/W2944524197> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2944524197 endingPage "1220" @default.
- W2944524197 startingPage "1214" @default.
- W2944524197 abstract "Purpose Nemiralisib, a phosphoinositide 3-kinase δ inhibitor, is being investigated as an immunomodulatory agent with anti-inflammatory properties in chronic obstructive pulmonary disease. This study evaluated the pharmacokinetic (PK) properties and safety of a new formulation of nemiralisib that contains 0.4% magnesium stearate. Methods In this randomized, double-blind, parallel-group study, healthy individuals received a single dose of 500 or 750 μg of nemiralisib administered via the Ellipta dry powder inhaler (DPI) (n = 6 in each treatment group). Aerodynamic particle size distribution (APSD) data comparing previous and new formulations were available before the study. Serial PK analyses for plasma exposure and safety assessments were performed during the first 24 h after dosing, with follow-up measurements on days 3 and 6 in clinic. Findings APSD had increases of approximately 6-fold and 2-fold in very fine particle mass and fine particle mass over the previous (Diskus) formulation. In humans, systemic exposure (AUC) was greater after inhalation of 750 versus 500 μg of nemiralisib (AUC0–t: 17,200 h∙pg/mL; 95% CI, 10,900–27,200 h∙pg/mL and 13,100; 95% CI, 8130–21,000 h∙pg/mL, respectively). A low frequency of individual adverse events and no serious adverse events were reported after both doses. Implications After single-dose inhalation of 500 and 750 μg of nemiralisib from the Ellipta DPI in healthy individuals, plasma PK data were well defined, and as predicted based on previous PK and APSD data, exposure was increased with the new formulation. Nemiralisib was well tolerated with no new safety issues identified. These data supported progression of nemiralisib to a Phase IIb study in patients with chronic obstructive pulmonary disease. ClinicalTrials.gov identifier: NCT03189589." @default.
- W2944524197 created "2019-05-16" @default.
- W2944524197 creator A5004353751 @default.
- W2944524197 creator A5011492468 @default.
- W2944524197 creator A5030942900 @default.
- W2944524197 creator A5033785127 @default.
- W2944524197 creator A5047225743 @default.
- W2944524197 creator A5067085873 @default.
- W2944524197 creator A5074110466 @default.
- W2944524197 date "2019-06-01" @default.
- W2944524197 modified "2023-09-23" @default.
- W2944524197 title "Safety, Tolerability, and Pharmacokinetics of a New Formulation of Nemiralisib Administered via a Dry Powder Inhaler to Healthy Individuals" @default.
- W2944524197 cites W1135839845 @default.
- W2944524197 cites W1917160907 @default.
- W2944524197 cites W2020022405 @default.
- W2944524197 cites W2401306489 @default.
- W2944524197 cites W2746637007 @default.
- W2944524197 cites W2884986851 @default.
- W2944524197 cites W2896365094 @default.
- W2944524197 cites W2920952786 @default.
- W2944524197 doi "https://doi.org/10.1016/j.clinthera.2019.04.008" @default.
- W2944524197 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31076203" @default.
- W2944524197 hasPublicationYear "2019" @default.
- W2944524197 type Work @default.
- W2944524197 sameAs 2944524197 @default.
- W2944524197 citedByCount "13" @default.
- W2944524197 countsByYear W29445241972019 @default.
- W2944524197 countsByYear W29445241972020 @default.
- W2944524197 countsByYear W29445241972021 @default.
- W2944524197 countsByYear W29445241972022 @default.
- W2944524197 countsByYear W29445241972023 @default.
- W2944524197 crossrefType "journal-article" @default.
- W2944524197 hasAuthorship W2944524197A5004353751 @default.
- W2944524197 hasAuthorship W2944524197A5011492468 @default.
- W2944524197 hasAuthorship W2944524197A5030942900 @default.
- W2944524197 hasAuthorship W2944524197A5033785127 @default.
- W2944524197 hasAuthorship W2944524197A5047225743 @default.
- W2944524197 hasAuthorship W2944524197A5067085873 @default.
- W2944524197 hasAuthorship W2944524197A5074110466 @default.
- W2944524197 hasConcept C112705442 @default.
- W2944524197 hasConcept C126322002 @default.
- W2944524197 hasConcept C197934379 @default.
- W2944524197 hasConcept C2776042228 @default.
- W2944524197 hasConcept C2776954882 @default.
- W2944524197 hasConcept C2777288759 @default.
- W2944524197 hasConcept C2777419714 @default.
- W2944524197 hasConcept C2778375690 @default.
- W2944524197 hasConcept C2780261241 @default.
- W2944524197 hasConcept C42219234 @default.
- W2944524197 hasConcept C71924100 @default.
- W2944524197 hasConcept C98274493 @default.
- W2944524197 hasConceptScore W2944524197C112705442 @default.
- W2944524197 hasConceptScore W2944524197C126322002 @default.
- W2944524197 hasConceptScore W2944524197C197934379 @default.
- W2944524197 hasConceptScore W2944524197C2776042228 @default.
- W2944524197 hasConceptScore W2944524197C2776954882 @default.
- W2944524197 hasConceptScore W2944524197C2777288759 @default.
- W2944524197 hasConceptScore W2944524197C2777419714 @default.
- W2944524197 hasConceptScore W2944524197C2778375690 @default.
- W2944524197 hasConceptScore W2944524197C2780261241 @default.
- W2944524197 hasConceptScore W2944524197C42219234 @default.
- W2944524197 hasConceptScore W2944524197C71924100 @default.
- W2944524197 hasConceptScore W2944524197C98274493 @default.
- W2944524197 hasFunder F4320307773 @default.
- W2944524197 hasIssue "6" @default.
- W2944524197 hasLocation W29445241971 @default.
- W2944524197 hasLocation W29445241972 @default.
- W2944524197 hasOpenAccess W2944524197 @default.
- W2944524197 hasPrimaryLocation W29445241971 @default.
- W2944524197 hasRelatedWork W1552942501 @default.
- W2944524197 hasRelatedWork W161684114 @default.
- W2944524197 hasRelatedWork W2007246196 @default.
- W2944524197 hasRelatedWork W2162130040 @default.
- W2944524197 hasRelatedWork W3093423188 @default.
- W2944524197 hasRelatedWork W3093464484 @default.
- W2944524197 hasRelatedWork W3110008058 @default.
- W2944524197 hasRelatedWork W4249858658 @default.
- W2944524197 hasRelatedWork W4386233607 @default.
- W2944524197 hasRelatedWork W2185565026 @default.
- W2944524197 hasVolume "41" @default.
- W2944524197 isParatext "false" @default.
- W2944524197 isRetracted "false" @default.
- W2944524197 magId "2944524197" @default.
- W2944524197 workType "article" @default.